IDEXX Laboratories, Inc.
NMS: IDXXLive Quote
📈 ZcoreAI Score
Our AI model analyzes IDEXX Laboratories, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get IDXX Z-Score →About IDEXX Laboratories, Inc.
Healthcare
Diagnostics & Research
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
📊 Fundamental Analysis
IDEXX Laboratories, Inc. demonstrates exceptional profitability, with a profit margin of 24.6%.
The company recently reported 14.3% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is 66.2%, which reflects exceptional capital efficiency.
At a current price of $563.00, IDXX currently sits at the 45th percentile of its 52-week range (Range: $391.05 - $769.98).
💰 Valuation Insight
IDXX trades at a 72.4% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
✅
Return on Equity
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$44.83B
Trailing P/E
43.11
Forward P/E
34.28
Beta (5Y)
1.72
52W High
$769.98
52W Low
$391.05
Avg Volume
524K
Day High
Day Low